Diminished MYCN Dosage Endows Cavitary Transformation in Retinoblastoma
The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Authors
- Mingpeng Xu
- Xuyang Wen (ORCID: https://orcid.org/0000-0002-9794-4379)
- Xunda Ji (ORCID: https://orcid.org/0000-0003-1684-1173)
- Peiquan Zhao (ORCID: https://orcid.org/0000-0002-5092-9550)
- Peiwei Chai (ORCID: https://orcid.org/0000-0002-9135-0940)
- Jiayan Fan
- Hanhan Shi (ORCID: https://orcid.org/0000-0001-9380-489X)
- Chuandi Zhou (ORCID: https://orcid.org/0000-0002-7267-6291)
- Yongning Shen
- Minglei Han (ORCID: https://orcid.org/0000-0002-0020-0825)
- Ludi Yang (ORCID: https://orcid.org/0000-0002-4451-9790)
- Xiang Gu
- Renbing Jia
- Yu Luan
Institutions
- Shanghai Jiao Tong University (CN)
- XinHua Hospital (CN)
- Shanghai Eye Disease Prevention & Treatment Center (CN)
- Shanghai Ninth People's Hospital (CN)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1016/j.xops.2025.100820
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00